TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Argent Biopharma ( (AU:RGT) ) is now available.
Argent BioPharma Ltd. has secured an A$11 million financing facility from US-based C/M Capital to complete the strategic acquisition of AusCann Group assets. This acquisition will provide Argent with access to valuable drug delivery technology, a manufacturing facility in Europe, and a German distribution network, enhancing its market entry and growth in Europe. The funding also positions Argent for a dual listing on a major U.S. stock exchange, while board changes are set to align with the new company strategy. This strategic financial move is expected to strengthen Argent’s operational and financial position, supporting its growth as a globally focused biopharmaceutical company.
More about Argent Biopharma
Argent BioPharma Ltd. is a biopharmaceutical company focused on developing and commercializing cannabinoid-based therapies. The company is known for its leading products, CannEpil and CimetrA, and targets markets in North and South America.
YTD Price Performance: -55.29%
Average Trading Volume: 122,137
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.91M
For an in-depth examination of RGT stock, go to TipRanks’ Overview page.